Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus

Kam A. Newman, Mojtaba Akhtari

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Autoimmune neutropenia, caused by neutrophil-specific autoantibodies is a common phenomenon in autoimmune disorders such as Felty's syndrome and systemic lupus erythematosus. Felty's syndrome is associated with neutropenia and splenomegaly in seropositive rheumatoid arthritis which can be severe and with recurrent bacterial infections. Neutropenia is also common in systemic lupus erythematosus and it is included in the current systemic lupus classification criteria. The pathobiology of the autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus is complex, and it could be a major cause of morbidity and mortality due to increased risk of sepsis. Treatment should be individualized on the basis of patient's clinical situation, and prevention or treatment of the infection. Recombinant human granulocyte colony-stimulating factor is a safe and effective therapeutic modality in management of autoimmune neutropenia associated with Felty's syndrome and systemic lupus erythematosus, which stimulates neutrophil production. There is a slight increased risk of exacerbation of the underlying autoimmune disorder, and recombinant human granulocyte colony-stimulating factor dose and frequency should be adjusted at the lowest effective dose.

Original languageEnglish (US)
Pages (from-to)432-437
Number of pages6
JournalAutoimmunity Reviews
Volume10
Issue number7
DOIs
StatePublished - May 1 2011

Fingerprint

Felty Syndrome
Neutropenia
Systemic Lupus Erythematosus
Granulocyte Colony-Stimulating Factor
Neutrophils
Splenomegaly
Bacterial Infections
Autoantibodies
Rheumatoid Arthritis
Sepsis
Therapeutics
Morbidity
Mortality
Infection

Keywords

  • Autoimmunity
  • Felty's syndrome
  • G-CSF
  • Neutropenia
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus. / Newman, Kam A.; Akhtari, Mojtaba.

In: Autoimmunity Reviews, Vol. 10, No. 7, 01.05.2011, p. 432-437.

Research output: Contribution to journalReview article

Newman, Kam A. ; Akhtari, Mojtaba. / Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus. In: Autoimmunity Reviews. 2011 ; Vol. 10, No. 7. pp. 432-437.
@article{d57e05a707c94a4ab83918a12f273886,
title = "Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus",
abstract = "Autoimmune neutropenia, caused by neutrophil-specific autoantibodies is a common phenomenon in autoimmune disorders such as Felty's syndrome and systemic lupus erythematosus. Felty's syndrome is associated with neutropenia and splenomegaly in seropositive rheumatoid arthritis which can be severe and with recurrent bacterial infections. Neutropenia is also common in systemic lupus erythematosus and it is included in the current systemic lupus classification criteria. The pathobiology of the autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus is complex, and it could be a major cause of morbidity and mortality due to increased risk of sepsis. Treatment should be individualized on the basis of patient's clinical situation, and prevention or treatment of the infection. Recombinant human granulocyte colony-stimulating factor is a safe and effective therapeutic modality in management of autoimmune neutropenia associated with Felty's syndrome and systemic lupus erythematosus, which stimulates neutrophil production. There is a slight increased risk of exacerbation of the underlying autoimmune disorder, and recombinant human granulocyte colony-stimulating factor dose and frequency should be adjusted at the lowest effective dose.",
keywords = "Autoimmunity, Felty's syndrome, G-CSF, Neutropenia, Systemic lupus erythematosus",
author = "Newman, {Kam A.} and Mojtaba Akhtari",
year = "2011",
month = "5",
day = "1",
doi = "10.1016/j.autrev.2011.01.006",
language = "English (US)",
volume = "10",
pages = "432--437",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus

AU - Newman, Kam A.

AU - Akhtari, Mojtaba

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Autoimmune neutropenia, caused by neutrophil-specific autoantibodies is a common phenomenon in autoimmune disorders such as Felty's syndrome and systemic lupus erythematosus. Felty's syndrome is associated with neutropenia and splenomegaly in seropositive rheumatoid arthritis which can be severe and with recurrent bacterial infections. Neutropenia is also common in systemic lupus erythematosus and it is included in the current systemic lupus classification criteria. The pathobiology of the autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus is complex, and it could be a major cause of morbidity and mortality due to increased risk of sepsis. Treatment should be individualized on the basis of patient's clinical situation, and prevention or treatment of the infection. Recombinant human granulocyte colony-stimulating factor is a safe and effective therapeutic modality in management of autoimmune neutropenia associated with Felty's syndrome and systemic lupus erythematosus, which stimulates neutrophil production. There is a slight increased risk of exacerbation of the underlying autoimmune disorder, and recombinant human granulocyte colony-stimulating factor dose and frequency should be adjusted at the lowest effective dose.

AB - Autoimmune neutropenia, caused by neutrophil-specific autoantibodies is a common phenomenon in autoimmune disorders such as Felty's syndrome and systemic lupus erythematosus. Felty's syndrome is associated with neutropenia and splenomegaly in seropositive rheumatoid arthritis which can be severe and with recurrent bacterial infections. Neutropenia is also common in systemic lupus erythematosus and it is included in the current systemic lupus classification criteria. The pathobiology of the autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus is complex, and it could be a major cause of morbidity and mortality due to increased risk of sepsis. Treatment should be individualized on the basis of patient's clinical situation, and prevention or treatment of the infection. Recombinant human granulocyte colony-stimulating factor is a safe and effective therapeutic modality in management of autoimmune neutropenia associated with Felty's syndrome and systemic lupus erythematosus, which stimulates neutrophil production. There is a slight increased risk of exacerbation of the underlying autoimmune disorder, and recombinant human granulocyte colony-stimulating factor dose and frequency should be adjusted at the lowest effective dose.

KW - Autoimmunity

KW - Felty's syndrome

KW - G-CSF

KW - Neutropenia

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=79955106414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955106414&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2011.01.006

DO - 10.1016/j.autrev.2011.01.006

M3 - Review article

VL - 10

SP - 432

EP - 437

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 7

ER -